Kevin Dynan

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, Gillian Mead, John Forbes et al. · The Lancet · 2018 · 286 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Moderately Elevated Plasma Homocysteine, Methylenetetrahydrofolate Reductase Genotype, and Risk for Stroke, Vascular Dementia, and Alzheimer Disease in Northern Ireland

Stephen P. McIlroy, Kevin Dynan, John T. Lawson et al. · Stroke · 2002 · 230 citations · Full text

Medicine, Biochemistry, Neurology +16

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Rustam Al‐Shahi Salman, M. J. S. Dennis, PAG Sandercock et al. · The Lancet · 2019 · 195 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study

Shauna M. McCusker, Martin D. Curran, Kevin Dynan et al. · The Lancet · 2001 · 190 citations

Life Sciences, Genetics, Molecular Genetics +17

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Rustam Al‐Shahi Salman, David Minks, Dipayan Mitra et al. · The Lancet Neurology · 2019 · 89 citations · Full text

Medicine, Neurology, Pharmacotherapy +17